top of page
MaybeCBD.com slogan.png
Search

Another group of senators is calling on the Food and Drug Administration (FDA) to expediently implement regulations for CBD in order to protect consumers and free up the industry.

At a press conference on Tuesday, Sen. Richard Blumenthal (D-CT) said he is urging FDA to issue guidance so that CBD products can be lawfully marketed. He and five of his colleagues also sent a letter to FDA expressing their desire to speed up the rulemaking process.

While delivering his remarks, the senator showcased CBD-infused seltzer water, gummies and tinctures as examples of products that can be beneficial to consumers.

The FDA has made it clear that is has only approved one company for medical use and two for therapeutic use. Any views, opinions, thoughts, recommendations are not supported by FDA policy. The FDA has created a policy for marketing application on cannabis products.


This is a statement from the FDA themselves on the subject:

There is a significant interest in the development of therapies and other consumer products derived from cannabis and its components, including cannabidiol (CBD). FDA recognizes the potential opportunities that cannabis or cannabis-derived compounds may offer and acknowledges the significant interest in these possibilities. However, FDA is aware that some companies are marketing products containing cannabis and cannabis-derived compounds in ways that violate the Federal Food, Drug and Cosmetic Act (FD&C Act) and that may put the health and safety of consumers at risk. The agency is committed to protecting the public health while also taking steps to improve the efficiency of regulatory pathways for the lawful marketing of appropriate cannabis and cannabis-derived products. FDA has a number of resources available that address cannabis and cannabis-derived products, such as CBD, and the agency wants to ensure that consumers and other stakeholders have access to these resources in a centralized location.



bottom of page